SELLAS Life Sciences Group Inc. (SLS) is navigating the latter half of 2025 with multiple clinical programs in motion and a clear focus on acute myeloid leukemia or AML.
The company's development strategy centers on two assets, Galinpepimut-S (GPS), a cancer immunotherapy targeting the WT1 antigen, and SLS009, a CDK9 inhibitor, both of which are being evaluated in AML across different stages of disease.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.